Octimibate

CAS No. 89838-96-0

Octimibate( —— )

Catalog No. M34007 CAS No. 89838-96-0

Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 342 In Stock
10MG 504 In Stock
25MG 816 In Stock
50MG 1097 In Stock
100MG 1479 In Stock
200MG Get Quote In Stock
500MG 2967 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Octimibate
  • Note
    Research use only, not for human use.
  • Brief Description
    Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist.
  • Description
    Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist.Octimibate is used in the treatment of cardiovascular disease and can be used to study atherosclerosis and thrombosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Prostaglandin Receptor
  • Recptor
    Prostaglandin Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    89838-96-0
  • Formula Weight
    454.56
  • Molecular Formula
    C29H30N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O(CCCCCCCC(O)=O)C=1N(C(=C(N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Terbogrel

    Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM).

  • AH 6809

    AH 6809 is an antagonist of EP and DP receptor(with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively).

  • L-798106

    L-798106 (CM9) is a selective and potent prostaglandin-like EP3 receptor antagonist that inhibits EP4, EP1, and EP2 receptors, suppresses levels of pro-inflammatory cytokines in atherosclerosis, and attenuates PGE2-induced cough.